Matrix protein 2 vaccination

[Anne]

EID Journal Home > Volume 13, Number 3?March 2007
<!-- InstanceEndEditable --><!-- content_starts_here //--> <!-- InstanceBeginEditable name="Article Content" --> Volume 13, Number 3?March 2007

whole article here :

http://www.cdc.gov/eid/content/13/3/426.htm

Research

Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1

Stephen Mark Tompkins,*¹ Zi-Shan Zhao,* Chia-Yun Lo,* Julia A. Misplon,* Teresa Liu,* Zhiping Ye,* Robert J. Hogan,? Zhengqi Wu,* Kimberly A. Benton,* Terrence M. Tumpey,? and Suzanne L. Epstein*
*Food and Drug Administration, Bethesda, Maryland, USA; ?University of Georgia, Athens, Georgia, USA; and ?Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Suggested citation for this article
Abstract
Changes in influenza viruses require regular reformulation of strain-specific influenza vaccines. Vaccines based on conserved antigens provide broader protection. Influenza matrix protein 2 (M2) is highly conserved across influenza A subtypes. To evaluate its efficacy as a vaccine candidate, we vaccinated mice with M2 peptide of a widely shared consensus sequence. This vaccination induced antibodies that cross-reacted with divergent M2 peptide from an H5N1 subtype. A DNA vaccine expressing full-length consensus-sequence M2 (M2-DNA) induced M2-specific antibody responses and protected against challenge with lethal influenza. Mice primed with M2-DNA and then boosted with recombinant adenovirus expressing M2 (M2-Ad) had enhanced antibody responses that cross-reacted with human and avian M2 sequences and produced T-cell responses. This M2 prime-boost vaccination conferred broad protection against challenge with lethal influenza A, including an H5N1 strain. Vaccination with M2, with key sequences represented, may provide broad protection against influenza A.

[Ganseerpel]

Re: Matrix protein 2 vaccination

A similar approach has already been suggested in 1999:

A universal influenza A vaccine based on the extracellular domain of the M2 protein.<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p>
Nat Med. 1999 Oct;5(10):1157-63. <o:p></o:p>
Comment in: <o:p></o:p>
Nat Med. 1999 Oct;5(10):1119-20.<o:p></o:p>
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=105028 19&dopt=Abstract<o:p></o:p>
Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W.<o:p></o:p>
<o:p></o:p>
Department of Molecular Biology, University of Ghent, K.L. Ledeganckstraat 35, 9000 Ghent, Belgium.<o:p></o:p>
<o:p></o:p>
The antigenic variation of influenza virus represents a major health problem. However, the extracellular domain of the minor, virus-coded M2 protein is nearly invariant in all influenza A strains. We genetically fused this M2 domain to the hepatitis B virus core (HBc) protein to create fusion gene coding for M2HBc; this gene was efficiently expressed in Escherichia coli. Intraperitoneal or intranasal administration of purified M2HBc particles to mice provided 90-100% protection against a lethal virus challenge. The protection was mediated by antibodies, as it was transferable by serum. The enhanced immunogenicity of the M2 extracellular domain exposed on HBc particles allows broad-spectrum, long-lasting protection against influenza A infections.<o:p></o:p>
<o:p></o:p>
PMID: 10502819 [PubMed - indexed for MEDLINE]<o:p></o:p>